International Centre for Ethics in the Sciences and Humanities, University of Tübingen, Tübingen, Germany.
Am J Bioeth. 2013;13(7):23-33. doi: 10.1080/15265161.2013.794875.
This article analyzes appropriate public policies for enhancement use of two most important stimulant drugs: Ritalin (methylphenidate) and Adderall (mixed amphetamine salts). The author argues that appropriate regulation of cognition enhancement drugs cannot be a result of a general discussion on cognitive enhancements as such, but has to be made on a case-by-case basis. Starting from the recently proposed taxation approach to cognition enhancement drugs, the author analyzes available, moderately permissive models of regulation. After a thorough analysis of relevant characteristics of methylphenidate and amphetamine, the author concludes that a moderately liberal permissive regulation of enhancement use by healthy adults might be appropriate for extended release forms of methylphenidate. However, due to their danger profile, amphetamine and instant release forms of methylphenidate should not be made readily available to healthy adults and would need to be prohibited.
本文分析了促进使用两种最重要的兴奋剂药物(利他林和安非他命)的适当公共政策。作者认为,对认知增强药物的适当监管不能是对认知增强本身的一般性讨论的结果,而必须根据具体情况做出决定。从最近提出的对认知增强药物征税的方法出发,作者分析了现有的、适度宽松的监管模式。在对利他林和安非他命的相关特征进行彻底分析后,作者得出结论,对于缓释形式的利他林,适度宽松的对健康成年人的使用进行监管可能是合适的。然而,由于其危险特征,安非他命和即时释放形式的利他林不应轻易提供给健康成年人,而需要被禁止。